Changes in Circulating Immunosuppressive Cytokine Levels of Cancer Patients After High Intensity Focused Ultrasound Treatment

Ultrasound in Medicine and Biology

Volumn 34, Issue 1, 2008, Pages 81-87

  Zhou, Qiang ^a   Zhu, Xue Qiang ^a   Zhang, Jun ^a   Xu, Zhong Lin ^a   Lu, Pei ^a   Wu, Feng ^a  

^a Institute of Ultrasonic Engineering in Medicine   (China)

Author keywords

Focused ultrasound surgery; High intensity focused ultrasound; Immunity; Immunosuppressive cytokine; Immunotherapy; Neoplasm; Thermal ablation; Ultrasound therapy

Indexed keywords

BIOASSAY; IMMUNOLOGY; MOLECULAR BIOLOGY; PATIENT TREATMENT; ULTRASONICS;

FOCUSED ULTRASOUND SURGERY; HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) TREATMENT; IMMUNOSUPPRESSIVE CYTOKINE; IMMUNOTHERAPY; NEOPLASM; THERMAL ABLATION; ULTRASOUND THERAPY;

ONCOLOGY;

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD LEVEL; CANCER; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY; ULTRASOUND; ULTRASOUND THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; ULTRASONIC THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37049016878     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2007.07.013     Document Type: Article

References (51)

1. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., and Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 166 (2001) 678-689
2. Barbieri C., Fujisawa M.M., Yasuda C.L., Metze I.L., Oliveira E.C., Santos L.M., Lopes L.R., and Andreollo N.A. Effect of surgical treatment on the cellular immune response of gastric cancer patients. Braz J Med Biol Res 36 (2003) 339-345
3. Chaussy C., Thuroff S., Rebillard X., and Gelet A. Technology insight: High-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2 (2005) 191-198
4. Chouaib S., Asselin-Paturel C., Mami-Chouraib F., Caignard A., and Blay J.Y. The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol Today 18 (1997) 493-497
5. Danna E.A., Sinha P., Gilbert M., Clements V.K., Pulaski B.A., and Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64 (2004) 2205-2211
6. Decker D., Tolba R., Springer W., Lauschke H., Hirner A., and von Ruecker A. Abdominal surgical interventions: Local and systemic consequences for the immune system- a prospective study on elective gastrointestinal surgery. J Surg Res 126 (2005) 12-18
7. Finke J., Ferrone S., Frey A., Mufson A., and Ochoa A. Where have all the T cells gone?. Mechanisms of immune evasion by tumors. Immunol Today 20 (1999) 158-160
8. Gabrilovich D., Ishida T., Oyama T., Nadaf S., Kerr L., Carbone D.P., and Gabrilovich D.I. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
9. Giannoudis P.V., Dinopoulos H., Chalidis B., and Hall G.M. Surgical stress response. Injury 37 Suppl 5 (2006) S3-S9
10. Gomez G.G., and Kruse C.A. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10 (2006) 133-146
11. Gridley D.S., Bonnet R.B., Bush D.A., Franke C., Cheek G.A., Slater J.D., and Slater J.M. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 759-766
12. Hattori E., Okumoto K., Adachi T., Takeda T., Ito J., Sugahara K., Watanabe H., Saito K., Saito T., Togashi H., and Kawata S. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatology Res 27 (2003) 308-313
13. Hu Z., Yang X.Y., Liu Y., Morse M.A., Lyerly H.K., Clay T.M., and Zhong P. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun 335 (2005) 124-131
14. Illing R.O., Kennedy J.E., Wu F., ter Haar G.R., Protheroe A.S., Friend P.J., Gleeson F.V., Cranston D.W., Phillips R.R., and Middleton M.R. The safety and feasibility of extracorporeal high intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumors in a Western population. Br J Cancer 93 (2005) 890-895
15. Jolesz F.A., Hynynen K., McDannold N., and Tempany C. MR imaging-controlled focused ultrasound ablation: A noninvasive image-guided surgery. Magn Reson Imaging Clin N Am 13 (2005) 545-560
16. Karayiannakis A.J., Syrigos K.N., Polychronidis A., Zbar A., Kouraklis G., Simopoulos C., and Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236 (2002) 37-42
17. Kennedy J.E., Wu F., ter Haar G.R., Gleeson F.V., Phillips R.R., Middleton M.R., and Cranston D. High-intensity focused ultrasound for the treatment of liver tumors. Ultrasonics 42 (2004) 931-935
18. Kennedy J.E. High-intensity focused ultrasound in the treatment of solid tumors. Nat Rev Cancer 5 (2005) 321-327
19. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999-1005
20. Kobie J.J., and Akporiaye E.T. Immunosuppressive role of transforming growth factor beta in breast cancer. Clin Applied Immunol Rev 3 (2003) 277-287
21. Kovacs C.J., Daly B.M., Evans M.J., Johnke R.M., Lee T.K., Karlsson U.L., Allison R., Eaves G.S., and Biggs L.M. Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23 21 (2003) 151-163
22. Kramer G., Steiner G.E., Grobl M., Hrachowitz K., Reithmayr F., Paucz L., Newman M., Madersbacher S., Gruber D., Susani M., and Marberger M. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate 58 (2004) 109-120
23. Kusmartsev S., and Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51 (2002) 293-298
24. Landman J., Olweny E., Sundaram C.P., Chen C., Rehman J., Lee D.I., Shalhav A., Portis A., McDougall E.M., and Clayman R.V. Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma. J Urol 171 (2004) 1456-1460
25. Mackall C.L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. Stem Cells 18 (2000) 10-18
26. Madersbacher S., Grobl M., Kramer G., Dirnhofer S., Steiner G.E., and Marberger M. Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate 37 (1998) 174-181
27. Marincola F.M., Jaffee E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 74 (2000) 181-273
28. Menger M.D., and Vollmar B. Surgical trauma: Hyperinflammation versus immunosuppression?. Langenbecks Arch Surg 389 (2004) 475-484
29. Messmann R.A., Ullmann C.D., Lahusen T., Kalehua A., Wasfy J., Melillo G., Ding I., Headlee D., Figg W.D., Sausville E.A., and Senderowicz A.M. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res 9 (2003) 562-570
30. Neuner A., Schindel M., Wildenberg U., Muley T., Lahm H., and Fischer J.R. Cytokine secretion: Clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 34 (2001) S79-S82
31. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., and Zinkernagel R.M. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
32. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
33. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., Valero V., Arun B., Ibrahim N., Rivera E., Royce M., Cleeland C.S., and Hortobagyi G.N. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25 (2004) 94-102
34. Rosberger D.F., Coleman D.J., Silverman R., Woods S., Rondeau M., and Cunningham-Rundles S. Immunomodulation in choroidal melanoma: Reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther 5 (1994) 59-68
35. Salvadori S., Martinelli G., and Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164 (2000) 2214-2220
36. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 (2000) 455-464
37. Shevach E.M. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2 (2002) 389-400
38. Sikora J.J., Dworacki G.T., Kaczmarek M.T., Jenek R.E., and Aeromski J.O. Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions. Cancer Detect Prev 28 (2004) 325-330
39. Steele T.A. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leuk Res 26 (2002) 411-414
40. Tilg H., Dinarello C.A., and Mier J.W. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 18 (1997) 428-432
41. Vallejo R., Hord E.D., Barna S.A., Santiago-Palma J., and Ahmed S. Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol 22 (2003) 139-146
42. van Sandick J.W., Gisbertz S.S., ten Berge I.J., Boermeester M.A., van der Pouw Kraan T.C., Out T.A., Obertop H., and van Lanschot J.J. Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. Ann Surg 237 (2003) 35-43
43. Whiteside T.L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16 (2006) 3-15
44. Wu F., Wang Z.B., Lu P., Xu Z.L., Chen W.Z., Zhu H., and Jin C.B. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 30 (2004) 1217-1222
45. Wu F., Wang Z.B., Chen W.Z., Zou J.Z., Bai J., Zhu H., Li K.Q., Xie F.L., Jin C.B., Su H.B., and Gao G.W. Extracorporeal focused ultrasound surgery for treatment of human solid carcinomas: Early Chinese clinical experience. Ultrasound Med Biol 30 (2004) 245-260
46. Wu F. Extracorporeal high intensity focused ultrasound in the treatment of patients with solid malignancy. Minim Invasive Ther Allied Technol 15 (2006) 26-35
47. Wu F., Zhou L., and Chen W.R. Host Antitumor immune responses to HIFU ablation. Int J Hyperthermia 23 (2007) 165-171
48. Wu F., Wang Z.B., Cao Y.D., Zhou Q., Zhang Y., Xu Z.L., and Zhu X.Q. Expression of tumor antigens and heat shock protein 70 in breast cancer cells after high intensity focused ultrasound ablation. Ann Surg Oncol 14 (2007) 1237-1242
49. Wang X., and Sun J. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chin Med J (Engl) 115 (2002) 1332-1335
50. Yang L., and Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92 (2004) 13-27
51. Yang R., Reilly C.R., Rescorla F.J., Sanghvi N.T., Fry F.J., Franklin Jr. T.D., and Grosfeld J.L. Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg 27 (1992) 246-251